Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Oncol. 1998 Jun;12(6):1299-306.

3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study.

Author information

  • 1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Abstract

3F8 is an IgG3 murine monoclonal antibody directed against the ganglioside GD2. In a phase II study, 3F8 was administered i.v. to 16 patients (pts) who had stage 4 neuroblastoma. Response was seen in bony lesions (2 of 7 pts) and marrow (3 of 8 pts). Acute toxicities of pain, fever, urticaria, hypertension, hypotension and anaphylactoid reactions were self-limited and manageable. Three pts are long-term survivors between 79-130+ months after 3F8 treatment without additional systemic therapy and no delayed neurological complications. The potential benefits of 3F8 when added to chemoradio-therapy warrant further investigation.

PMID:
9592190
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Spandidos Publications
    Loading ...
    Write to the Help Desk